Radiopharm Theranostics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RADX research report →
Range $6 – $6
Price Chart
About the company
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic.
- CEO
- Riccardo Canevari
- IPO
- 2024
- Employees
- 14
- HQ
- Carlton, VIC, AU
Get TickerSpark's AI analysis on RADX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $812.08K
- P/E
- -0.26
- Fwd P/E
- 0.27
- PEG
- -0.00
- P/S
- 3.42
- P/B
- 0.57
- EV/EBITDA
- -0.08
- Div Yield
- 0.00%
- Gross Margin
- -39.41%
- Op Margin
- -2545.78%
- Net Margin
- -1992.46%
- ROE
- -144.24%
- ROIC
- -158.08%
Latest fiscal year · YoY change
- Revenue
- $2.71M-25.5%
- Gross Profit
- $-2,102,918-5454.2%
- Op Income
- $-66,835,431
- Net Income
- $-53,944,069-40.7%
- EPS
- $-4.56+13.6%
- OCF Growth
- -40.9%
- FCF Growth
- +100.0%
- 52W High
- $16.25
- 52W Low
- $0.63
- 50D MA
- $1.18
- 200D MA
- $3.38
- Beta
- 0.80
- RSI (14)
- 29
- Avg Volume
- 55.78K
No earnings-call transcripts are available for RADX yet.
- Free Float
- 63.6%
- Shares Outstanding
- 1.29M
- Float Shares
- 819.52K
of shares held by institutions
7 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Hsbc Holdings PLC | 62.19K | ▲ 816 |
| Pnc Financial Services Group, Inc. | 50.00K | ▲ 30.00K |
| Regal Partners Ltd | 40.14K | 0 |
| Integrated Wealth Concepts LLC | 1.31K | ▲ 1.31K |
| Ubs Group AG | 883 | ▼ 624 |
| Quent Capital, LLC | 229 | ▲ 229 |
| Rhumbline Advisers | 195 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 19, 26 | Voliotis Dimitris | other | 10,295,667 |
| Oct 19, 26 | Voliotis Dimitris | other | 10,295,666 |
| Jul 1, 28 | Voliotis Dimitris | other | 0 |
| Jul 1, 27 | Voliotis Dimitris | other | 0 |
| Mar 18, 26 | HOPPER PAUL | other | 0 |
| Mar 18, 26 | HOPPER PAUL | other | 0 |
| Sep 13, 24 | HOPPER PAUL | other | 0 |
| Jul 1, 28 | HOPPER PAUL | other | 0 |
| Jul 1, 27 | HOPPER PAUL | other | 0 |
| Mar 18, 26 | HOPPER PAUL | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RADX coverage
Recent articles, reports, and earnings notes.
No research on RADX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RADX report →Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases
globenewswire.com · Nov 4
Radiopharm Theranostics Reports Business Update
globenewswire.com · Nov 2
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
globenewswire.com · Sep 9
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
globenewswire.com · Aug 26
Radiopharm Theranostics (NASDAQ:RADX) Trading Down 8.4% – What’s Next?
defenseworld.net · Aug 21
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
globenewswire.com · Aug 20
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
globenewswire.com · Jul 24
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
globenewswire.com · Jul 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.